Under the collaboration, University of Victoria researchers will add 2,000 new multiple reaction-monitoring mass spec assays to the CPTAC Assay Portal.
Announced this month, the project brings together CPTAC, the VA, and DoD, and has as its initial goal the proteogenomic analysis of 8,000 lung cancer patients.
The CPTAC study integrated proteomic and genomic data from 77 breast cancer tumors with the aim of identifying potential biomarkers and therapeutic targets.
Among other aims, the five-year effort hopes to use genomic and proteomic data to better understand patient drug response and the development of resistance.
The company plans to offer the immuno-MRM assays as kits covering sample prep and protein digestion as well as immuno-enrichment of specific peptides.
The organizations will use proteomics to characterize tumors and compare these proteomic characterizations to other forms of data including genomic profiles.
The sites will collect primary human tumors according to a protocol optimized for proteomics for the NCI's Clinical Proteomic Tumor Analysis Consortium.
The core will serve as a center for receiving, qualifying, processing, and distributing biospecimens to the Clinical Proteomic Tumor Analysis Consortium.
Researchers working onbreast, colorectal, and ovarian cancer highlighted their work, making the case for proteogenomic approaches to cancer research.
The project aims to develop multiple-reaction monitoring mass spec and immuno-MRM mass spec assays for roughly 100 proteins involved in RAS signaling.
Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.
Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.
Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.
In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.